Literature DB >> 32584722

Multidisciplinary approach in the treatment of osteoid osteoma with radiofrequency ablation.

Bülent Tanrıverdi1, Aysun Erbahçeci Salık, Halil Çetingök, Erdem Edipoğlu, Mustafa Gökhan Bilgili, Koray Güven, Filiz Saçan.   

Abstract

OBJECTIVES: This study aims to present the importance of a multidisciplinary approach to radiofrequency ablation (RFA) treatment in osteoid osteoma (OO) patients by a team of experts in their field in preventing recurrence and complications. PATIENTS AND METHODS: For this retrospective study, a team of two orthopedists, two interventional radiologists, and one anesthesiologist was established in January 2013 to manage the diagnosis, follow-up, and treatment process of patients with OO at Bakırköy Dr. Sadi Konuk Training and Research Hospital. A total of 27 patients (15 males, 12 females; mean age 22.9 years; range, 9 to 54 years) were treated by this team between February 2013 and September 2016. The anatomic localization included iliac crest in four patients, the femur in 12 patients, fibula in two patients, humerus in three patients, radius in one patient, tibia in three patients, talus in one patient, and metacarpal in one patient. The procedures were carried out by the same interventional radiologists, same orthopedic surgeons, and same anesthesiologist in the computed tomography (CT) unit under aseptic conditions. After appropriate anesthesia for the localization of OO, the patient was positioned on the CT bed and the localization of the lesion was confirmed with a CT scan mapping. Then, a bone penetration cannula was advanced and bone cortex was penetrated with a charged motor and Kirschner (K)-wire. When the cannula reached the nidus, it was replaced with RFA probe. Ablation of the nidus was performed for five minutes at 90°C.
RESULTS: The mean follow-up period was 46 months (range, 25 to 66 months). Patients were evaluated with visual analog scale (VAS) scores preoperatively and at postoperative 15th day, sixth month, and first year. In the last evaluation of the study data, the patients were called by telephone and questioned whether there were any changes in their final status. The mean preoperative VAS score was 7.2. The mean postoperative VAS scores of the 15th day, sixth month, and first year were 1.3, 0.6, and 0, respectively. In the last follow-up, the OO-related pain completely disappeared and none of the patients had any recurrence. There was a significant difference between preoperative and postoperative 15th day and sixth month VAS score measurements.
CONCLUSION: Radiofrequency ablation treatment of OOs is a minimally invasive, safe, low-cost, and efficient method. We believe that with experienced teams and appropriate planning, RFA will take part in practice as the standard treatment of OO.

Entities:  

Year:  2020        PMID: 32584722     DOI: 10.5606/ehc.2020.71413

Source DB:  PubMed          Journal:  Jt Dis Relat Surg        ISSN: 2687-4792


  5 in total

1.  The surgical management of osteoid osteoma: A systematic review.

Authors:  Man Shu; Jin Ke
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

2.  Osteoid Osteoma of Talus - A Rare Occurrence Mimicking Ankle Arthritis: A Case Report.

Authors:  Satvik N Pai; Mohan M Kumar; Pravin K Vanchi; Raghav Ravi
Journal:  J Orthop Case Rep       Date:  2022-02

3.  Effectiveness and reliability of traditional open surgery in atypical localizations of osteoid osteoma.

Authors:  Muhammet Salih Ayas; Orkun Gül; Ahmet Emin Okutan; Servet Kerimoğlu; Mehmet Yıldız; Ahmet Uğur Turhan; Osman Aynacı
Journal:  Jt Dis Relat Surg       Date:  2020

4.  Arthroscopic excision of intraarticular subperiosteal osteoid osteoma of talar neck: A case report.

Authors:  Bülent Özdemir; Sercan Akpınar
Journal:  Jt Dis Relat Surg       Date:  2020

Review 5.  Osteoid osteoma: which is the best mininvasive treatment option?

Authors:  Anna Parmeggiani; Claudia Martella; Luca Ceccarelli; Marco Miceli; Paolo Spinnato; Giancarlo Facchini
Journal:  Eur J Orthop Surg Traumatol       Date:  2021-04-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.